ADC Therapeutics SA Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine and Camidanlumab Tesirine Conference Call Transcript
Good morning, and welcome to the ADC Therapeutics webcast and conference call highlighting ADC Therapeutics' presentations at the ASH 2020 Virtual Meeting. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
At this time, I'd like to turn the call over to Amanda Hamilton, Investor Relations Manager.
Good morning, and welcome to our call. Earlier this morning, we issued a press release announcing our updated clinical data on our lead antibody drug conjugate programs, Lonca and Cami. This release as well as a replay of today's webcast, including slides, will be available on the Investors section of our website at www.adctherapeutics.com.
As a reminder, during today's call, we will be making forward-looking statements. All statements other than statements of historical facts are forward-looking statements. Such statements are subject to risks and uncertainties, and actual
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |